Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron once-daily versus placebo in adults with type 2 diabetes mellitus and overweight or obesity
CTR20252895Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and Overweight comparing Orforglipron with Placebo (2 arms). Primary endpoint: Change from baseline in hemoglobin A1c. Started Aug 2025; status: active.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on CTR20252895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252895.